CEO
R. Nolan Townsend is the Chief Executive Officer and a Class III Director at Lexeo Therapeutics, Inc. (NASDAQ: LXEO), a clinical-stage biotechnology company developing gene therapies for cardiovascular diseases, genetically defined cardiovascular conditions, CNS disorders including Alzheimer’s disease, and rare genetic diseases, a role he has held since January 2020.[[1]](https://fintool.com/app/research/companies/LXEO/people/r-nolan-townsend)[[2]](https://www.youtube.com/watch?v=O2CLnEhEe3k)[[4]](https://arbor.bio/arbor-biotechnologies-appoints-industry-veteran-r-nolan-townsend-to-board-of-directors/)[[5]](https://www.lexeotx.com/team/)
Prior to joining Lexeo, Townsend spent over a decade at Pfizer Inc. from 2008 to December 2019, advancing through roles in finance, corporate strategy, operations, marketing, and general management across regions including North America, Asia, Africa/Middle East, and Europe, culminating as President of Pfizer Rare Disease for North America and International markets, where he oversaw strategy, cross-functional teams, and operating budgets.[[1]](https://fintool.com/app/research/companies/LXEO/people/r-nolan-townsend)[[2]](https://www.youtube.com/watch?v=O2CLnEhEe3k)[[3]](https://wewillcure.com/insights/entrepreneurship/founder-stories/mvp-insights_article-global-perspective-top-3-leadership-lessons-from-lexeo)[[4]](https://arbor.bio/arbor-biotechnologies-appoints-industry-veteran-r-nolan-townsend-to-board-of-directors/) He began his career in healthcare investment banking at Lehman Brothers.[[2]](https://www.youtube.com/watch?v=O2CLnEhEe3k) Townsend holds a B.A. in Economics from the University of Pennsylvania and an M.B.A. from Harvard Business School.[[1]](https://fintool.com/app/research/companies/LXEO/people/r-nolan-townsend)[[2]](https://www.youtube.com/watch?v=O2CLnEhEe3k) He serves on the boards of Arbor Biotechnologies, the Biotechnology Innovation Organization (BIO), and the Martha’s Vineyard Museum, and is a member of the New York City Economic Development Corporation’s Life Sciences Advisory Council.[[1]](https://fintool.com/app/research/companies/LXEO/people/r-nolan-townsend)[[2]](https://www.youtube.com/watch?v=O2CLnEhEe3k) Recently, as a corporate insider, he sold 10,173 shares of LXEO stock on February 18, 2026, at $6.38 per share, valued at approximately $64,903.[[6]](https://www.tipranks.com/news/insider-trading/top-brass-at-biotech-player-quietly-cash-out-in-latest-insider-move-insider-trading-news)[[7]](https://www.marketbeat.com/instant-alerts/insider-selling-lexeo-therapeutics-nasdaqlxeo-ceo-sells-10173-shares-of-stock-2026-02-20/)
View full insider profile →
